<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242710</url>
  </required_header>
  <id_info>
    <org_study_id>3115A1-304</org_study_id>
    <nct_id>NCT00242710</nct_id>
  </id_info>
  <brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bazedoxifene/conjugated estrogens
      combinations are effective for the prevention of endometrial hyperplasia and for the
      prevention of osteoporosis in postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Hyperplasia at Screening</measure>
    <time_frame>Screening</time_frame>
    <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hyperplasia at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) of Lumbar Spine at Screening</measure>
    <time_frame>Screening</time_frame>
    <description>BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) of Total Hip at Screening</measure>
    <time_frame>Screening</time_frame>
    <description>BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Breast Pain</measure>
    <time_frame>Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52</time_frame>
    <description>Percentage of days with breast pain in each 4-week period (for example, Week 1 to 4, 5 to 8) calculated as the number of days on which a participants reported breast pain divided by total number of days with data recorded multiplied by 100. Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Uterine Bleeding or Spotting</measure>
    <time_frame>Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52</time_frame>
    <description>Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hyperplasia at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 24</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 24</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>BMD measurements of the total hip were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1083</enrollment>
  <condition>Endometrial Hyperplasia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BZA 20mg/CE 0.625</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BZA 20mg/CE 0.45</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CE 0.45mg/MPA1.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene/Conjugated Estrogen</intervention_name>
    <description>Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene/Conjugated Estrogen</intervention_name>
    <description>Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE 0.45 mg/MPA 1.5mg</intervention_name>
    <description>Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy, postmenopausal women, aged 40 to less than 65 years

          -  Intact uterus

          -  At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with
             follicle-stimulating hormone (FSH) levels &gt; 40 mIU/mL.

        Exclusion Criteria:

          -  Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within
             8 weeks before screening (12 weeks for the osteoporosis substudy)

          -  A history or active presence of clinically important medical disease

          -  Malabsorption disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3115A1-304&amp;StudyName=Study%20Evaluating%20Bazedoxifene/Conjugated%20Estrogens%20Combinations%20In%20Postmenopausal%20Women</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <results_first_submitted>October 30, 2013</results_first_submitted>
  <results_first_submitted_qc>October 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2013</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrium</keyword>
  <keyword>Uterus</keyword>
  <keyword>Menopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Bazedoxifene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This main study also included osteoporosis substudy only for the purpose of the assessment of relevant parameters.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
          <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
        </group>
        <group group_id="P2">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
          <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="P3">
          <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
          <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study (up to Year 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
                <participants group_id="P2" count="353"/>
                <participants group_id="P3" count="183"/>
                <participants group_id="P4" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="349"/>
                <participants group_id="P3" count="179"/>
                <participants group_id="P4" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not Treated</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period Between Core Study and Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Extension not Available</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Extension (up to Year 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all randomly assigned participants who took at least 1 dose of test article.</population>
      <group_list>
        <group group_id="B1">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
          <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
        </group>
        <group group_id="B2">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
          <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="B3">
          <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
          <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="361"/>
            <count group_id="B2" value="349"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="172"/>
            <count group_id="B5" value="1061"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.62" spread="4.74"/>
                    <measurement group_id="B2" value="54.44" spread="4.62"/>
                    <measurement group_id="B3" value="54.30" spread="4.56"/>
                    <measurement group_id="B4" value="54.19" spread="4.62"/>
                    <measurement group_id="B5" value="54.44" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="172"/>
                    <measurement group_id="B5" value="1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hyperplasia at Screening</title>
        <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
        <time_frame>Screening</time_frame>
        <population>Endometrial hyperplasia at screening was an exclusion criterion and participants who had hyperplasia were not included in the analysis. Therefore this data is not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hyperplasia at Screening</title>
          <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
          <population>Endometrial hyperplasia at screening was an exclusion criterion and participants who had hyperplasia were not included in the analysis. Therefore this data is not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hyperplasia at Month 12</title>
        <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
        <time_frame>Month 12</time_frame>
        <population>Efficacy evaluable (EE) analysis population for Year 1: all participants who were randomized and took at least 1 dose of test article, who had a screening endometrial biopsy with readings by at least 2 blinded central pathologists, had a biopsy during Month 12, or had hyperplasia diagnosed before Month 12 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hyperplasia at Month 12</title>
          <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
          <population>Efficacy evaluable (EE) analysis population for Year 1: all participants who were randomized and took at least 1 dose of test article, who had a screening endometrial biopsy with readings by at least 2 blinded central pathologists, had a biopsy during Month 12, or had hyperplasia diagnosed before Month 12 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.30" upper_limit="2.82"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="2.49"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) of Lumbar Spine at Screening</title>
        <description>BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Screening</time_frame>
        <population>Modified intent-to-treat (MITT) population for BMD of lumber spine included all randomized participants took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) of Lumbar Spine at Screening</title>
          <description>BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>Modified intent-to-treat (MITT) population for BMD of lumber spine included all randomized participants took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1.</population>
          <units>grams per square centimeter (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.12"/>
                    <measurement group_id="O2" value="1.01" spread="0.12"/>
                    <measurement group_id="O3" value="1.02" spread="0.12"/>
                    <measurement group_id="O4" value="1.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12</title>
        <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>MITT population for BMD of lumber spine: all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after test article administration was stopped were excluded) at Year 1. Missing values imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12</title>
          <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>MITT population for BMD of lumber spine: all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after test article administration was stopped were excluded) at Year 1. Missing values imputed using last observation carried forward (LOCF).</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.24"/>
                    <measurement group_id="O2" value="0.80" spread="0.24"/>
                    <measurement group_id="O3" value="2.22" spread="0.37"/>
                    <measurement group_id="O4" value="-1.56" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance (ANCOVA) model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.81</ci_lower_limit>
            <ci_upper_limit>4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) of Total Hip at Screening</title>
        <description>BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Screening</time_frame>
        <population>MITT population for BMD of total hip included all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1. Missing values were imputed using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) of Total Hip at Screening</title>
          <description>BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>MITT population for BMD of total hip included all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1. Missing values were imputed using LOCF method.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.11"/>
                    <measurement group_id="O2" value="0.89" spread="0.11"/>
                    <measurement group_id="O3" value="0.90" spread="0.10"/>
                    <measurement group_id="O4" value="0.89" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12</title>
        <description>BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>MITT population for BMD of total hip included all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1. Missing values were imputed using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12</title>
          <description>BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>MITT population for BMD of total hip included all randomized participants who took at least 1 dose of test article, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 1. Missing values were imputed using LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.19"/>
                    <measurement group_id="O2" value="0.84" spread="0.19"/>
                    <measurement group_id="O3" value="1.47" spread="0.29"/>
                    <measurement group_id="O4" value="-0.99" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Breast Pain</title>
        <description>Percentage of days with breast pain in each 4-week period (for example, Week 1 to 4, 5 to 8) calculated as the number of days on which a participants reported breast pain divided by total number of days with data recorded multiplied by 100. Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
        <time_frame>Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52</time_frame>
        <population>MITT population for breast pain: all randomized participants who took at least 1 dose of test article, and had data available at least for 5 of 7 days at screening and 20 days for at least 1 post-baseline interval. n=participants evaluable at specified time periods for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Breast Pain</title>
          <description>Percentage of days with breast pain in each 4-week period (for example, Week 1 to 4, 5 to 8) calculated as the number of days on which a participants reported breast pain divided by total number of days with data recorded multiplied by 100. Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
          <population>MITT population for breast pain: all randomized participants who took at least 1 dose of test article, and had data available at least for 5 of 7 days at screening and 20 days for at least 1 post-baseline interval. n=participants evaluable at specified time periods for each arm, respectively.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-4 (n=347, 329, 168, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.49"/>
                    <measurement group_id="O2" value="1.22" spread="0.51"/>
                    <measurement group_id="O3" value="3.49" spread="0.65"/>
                    <measurement group_id="O4" value="0.89" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8 (n=331, 323, 158, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.68"/>
                    <measurement group_id="O2" value="1.58" spread="0.68"/>
                    <measurement group_id="O3" value="5.54" spread="0.91"/>
                    <measurement group_id="O4" value="1.36" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12 (n=323, 317, 150, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.68"/>
                    <measurement group_id="O2" value="1.01" spread="0.68"/>
                    <measurement group_id="O3" value="4.80" spread="0.93"/>
                    <measurement group_id="O4" value="1.36" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-16 (n=315, 310, 141, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.60"/>
                    <measurement group_id="O2" value="0.88" spread="0.61"/>
                    <measurement group_id="O3" value="3.92" spread="0.84"/>
                    <measurement group_id="O4" value="0.77" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17-20 (n=313, 309, 141, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.63"/>
                    <measurement group_id="O2" value="1.57" spread="0.64"/>
                    <measurement group_id="O3" value="4.23" spread="0.88"/>
                    <measurement group_id="O4" value="1.61" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21-24 (n=312, 306, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.78"/>
                    <measurement group_id="O2" value="1.85" spread="0.79"/>
                    <measurement group_id="O3" value="5.01" spread="1.08"/>
                    <measurement group_id="O4" value="1.26" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-28 (n=306, 298, 136, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.77"/>
                    <measurement group_id="O2" value="1.31" spread="0.78"/>
                    <measurement group_id="O3" value="4.91" spread="1.07"/>
                    <measurement group_id="O4" value="1.39" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29-32 (n=301, 297, 133, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.62"/>
                    <measurement group_id="O2" value="0.82" spread="0.63"/>
                    <measurement group_id="O3" value="3.98" spread="0.87"/>
                    <measurement group_id="O4" value="0.17" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33-36 (n=297, 294, 132, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.57"/>
                    <measurement group_id="O2" value="0.25" spread="0.58"/>
                    <measurement group_id="O3" value="3.49" spread="0.80"/>
                    <measurement group_id="O4" value="-0.26" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-40 (n=295, 288, 130, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.62"/>
                    <measurement group_id="O2" value="0.25" spread="0.64"/>
                    <measurement group_id="O3" value="3.87" spread="0.88"/>
                    <measurement group_id="O4" value="0.57" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41-44 (n=286, 285, 128, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.66"/>
                    <measurement group_id="O2" value="0.56" spread="0.67"/>
                    <measurement group_id="O3" value="2.49" spread="0.92"/>
                    <measurement group_id="O4" value="0.86" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45-48 (n=282, 284, 127, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.67"/>
                    <measurement group_id="O2" value="1.26" spread="0.68"/>
                    <measurement group_id="O3" value="2.52" spread="0.94"/>
                    <measurement group_id="O4" value="1.17" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49-52 (n=170, 171, 70, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.12"/>
                    <measurement group_id="O2" value="1.68" spread="1.16"/>
                    <measurement group_id="O3" value="5.27" spread="1.69"/>
                    <measurement group_id="O4" value="1.49" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.539</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.605</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.305</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>3.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.279</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.260</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.618</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.810</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.78</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.834</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.909</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.947</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.739</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.931</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.92</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>4.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>6.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>5.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>4.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>6.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>6.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>5.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>3.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: An ANCOVA model was used with treatment, center as factors, and baseline as the covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>7.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Uterine Bleeding or Spotting</title>
        <description>Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
        <time_frame>Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52</time_frame>
        <population>MITT population for uterine bleeding or spotting included all randomized participants who had received at least 1 dose of test article and had at least 1 day of on-therapy bleeding data. Imputation=LOCF. n=participants evaluable for this measure at specified time periods for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Uterine Bleeding or Spotting</title>
          <description>Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.</description>
          <population>MITT population for uterine bleeding or spotting included all randomized participants who had received at least 1 dose of test article and had at least 1 day of on-therapy bleeding data. Imputation=LOCF. n=participants evaluable for this measure at specified time periods for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-4 (n=330, 313, 159, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45"/>
                    <measurement group_id="O2" value="4.15"/>
                    <measurement group_id="O3" value="19.50"/>
                    <measurement group_id="O4" value="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-8 (n=320, 315, 153, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19"/>
                    <measurement group_id="O2" value="2.86"/>
                    <measurement group_id="O3" value="23.53"/>
                    <measurement group_id="O4" value="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-12 (n=316, 310, 147, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53"/>
                    <measurement group_id="O2" value="4.52"/>
                    <measurement group_id="O3" value="25.17"/>
                    <measurement group_id="O4" value="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-16 (n=310, 296, 137, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90"/>
                    <measurement group_id="O2" value="2.70"/>
                    <measurement group_id="O3" value="16.79"/>
                    <measurement group_id="O4" value="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17-20 (n=315, 311, 144, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                    <measurement group_id="O2" value="1.61"/>
                    <measurement group_id="O3" value="16.67"/>
                    <measurement group_id="O4" value="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21-24 (n=311, 306, 142, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                    <measurement group_id="O2" value="1.31"/>
                    <measurement group_id="O3" value="16.20"/>
                    <measurement group_id="O4" value="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-28 (n=294, 290, 131, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04"/>
                    <measurement group_id="O2" value="1.38"/>
                    <measurement group_id="O3" value="9.92"/>
                    <measurement group_id="O4" value="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29-32 (n=298, 297, 135, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67"/>
                    <measurement group_id="O2" value="2.02"/>
                    <measurement group_id="O3" value="11.11"/>
                    <measurement group_id="O4" value="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33-36 (n=296, 291, 134, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03"/>
                    <measurement group_id="O2" value="2.75"/>
                    <measurement group_id="O3" value="11.94"/>
                    <measurement group_id="O4" value="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-40 (n=282, 279, 131, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13"/>
                    <measurement group_id="O2" value="2.87"/>
                    <measurement group_id="O3" value="11.45"/>
                    <measurement group_id="O4" value="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41-44 (n=285, 284, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40"/>
                    <measurement group_id="O2" value="1.06"/>
                    <measurement group_id="O3" value="8.33"/>
                    <measurement group_id="O4" value="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45-48 (n=280, 282, 130, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79"/>
                    <measurement group_id="O2" value="2.48"/>
                    <measurement group_id="O3" value="11.54"/>
                    <measurement group_id="O4" value="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49-52 (n=45, 51, 15, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.96"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.534</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.446</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.736</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.489</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.448</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.507</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.689</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.437</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.554</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-4: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 5-8: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 9-12: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 13-16: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 17-20: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 21-24: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 25-28: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 29-32: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 33-36: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 37-40: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 41-44: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 45-48: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 49-52: The Fisher exact test was used for comparisons between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hyperplasia at Month 24</title>
        <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
        <time_frame>Month 24</time_frame>
        <population>EE analysis population for Year 2 included all randomized participants who took at least 1 dose of test article, participated in study extension, had a screening endometrial biopsy with readings by at least 2 blinded central pathologists, had biopsy during Month 24, or had hyperplasia diagnosed before Month 24 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hyperplasia at Month 24</title>
          <description>Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.</description>
          <population>EE analysis population for Year 2 included all randomized participants who took at least 1 dose of test article, participated in study extension, had a screening endometrial biopsy with readings by at least 2 blinded central pathologists, had biopsy during Month 24, or had hyperplasia diagnosed before Month 24 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="2.78"/>
                    <measurement group_id="O2" value="4.93" lower_limit="2.00" upper_limit="9.89"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="5.44"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 24</title>
        <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>MITT population for BMD of lumber spine: all participants who took at least 1 dose of test article, participated in study extension, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 2. Missing values imputed using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 24</title>
          <description>BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>MITT population for BMD of lumber spine: all participants who took at least 1 dose of test article, participated in study extension, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 2. Missing values imputed using LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.40"/>
                    <measurement group_id="O2" value="0.86" spread="0.41"/>
                    <measurement group_id="O3" value="2.39" spread="0.57"/>
                    <measurement group_id="O4" value="-2.29" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 24</title>
        <description>BMD measurements of the total hip were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>MITT population for BMD of total hip: all participants who took at least 1 dose of test article, participated in study extension, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 2. Missing values imputed using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
            <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
          </group>
          <group group_id="O2">
            <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
            <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
            <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 24</title>
          <description>BMD measurements of the total hip were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.</description>
          <population>MITT population for BMD of total hip: all participants who took at least 1 dose of test article, participated in study extension, and had a baseline and at least 1 on-therapy evaluation of BMD (scans acquired more than 60 days after the test article administration was stopped were excluded) at Year 2. Missing values imputed using LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.31"/>
                    <measurement group_id="O2" value="0.41" spread="0.32"/>
                    <measurement group_id="O3" value="0.85" spread="0.44"/>
                    <measurement group_id="O4" value="-1.53" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA model was used with treatment and center as main effects and baseline BMD and years since menopause as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg</title>
          <description>Bazedoxifene 20 milligram (mg)/conjugated estrogen 0.45 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 international unit (IU) orally once daily up to Year 2.</description>
        </group>
        <group group_id="E2">
          <title>Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg</title>
          <description>Bazedoxifene 20 mg/conjugated estrogen 0.625 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="E3">
          <title>Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg</title>
          <description>Conjugated estrogen 0.45 mg/medroxyprogesterone acetate 1.5 mg capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo matched to bazedoxifene/conjugated estrogen or conjugated estrogen/medroxyprogesterone acetate capsule orally once daily at approximately the same time each day continuously up to Year 1 during the core study and up to Year 2 during the study extension. Participants also received Caltrate plus D tablet containing calcium 600 mg and vitamin D 200 IU orally once daily up to Year 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy endometrium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA v11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="322" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="309" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="152" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

